News

COVID-19 has amplified the growing importance of advanced practice providers as demands for healthcare increase and a national physician shortage looms.

The first of a two-part story on 10 takeaways about the telehealth boom. The COVID-19 pandemic has been a bumpy ride in the U.S., featuring one controversy after another. One of the few areas of agreement is that the widespread adoption of telehealth amid the pandemic has been, by and large, a positive development.

In this week’s episode, MHE's Briana Contreras spoke with Anthony Gabriel, M.D., MBA, chief operating officer at Radiology Partners. Anthony shared the importance of health entities having physicians in the C-Suite, or executive levels in their health organizations, as Radiology Partners does. He and Briana also discussed what type of training a health professional needs to get to this level and some decisions he’s made as a health professional in the C-Suite.

Like a marathon with runners you don't know who will come in first until the end, health plans and providers share a similarity when they look at all the patients/members whose chronic conditions have taken a back seat to battling the COVID-19 pandemic.

There’s some skepticism as programs to address social determinants of health proliferate. Some data are being collected.

Therapies that target lung cancer at the molecular level are proliferating — and so are the biomarkers for guiding their use.

FDA official says the approval is important because of the combination of the flu season and the COVID-19 pandemic.

Regeneron's investigational treatment was administered to President Donald Trump in October when he was treated for COVID-19.

In the early going, patients seeking the expensive, customized cancer treatments called CAR-T cell therapy had to go to an academic medical center. But that’s changing, as Duncan Allen, M.H.A., of the community cancer network OneOncology explains.

Leanne Berge, CEO of Community Health Plan of Washington in Seattle, talks to Managed Healthcare Executive about patient access challenges, COVID-19, telehealth, and health care disparities.

Health plans build strategies to ensure their beneficiaries have easy access to and receive vital immunizations.

If Pfizer's vaccine gets an emergency use authorization, it could reach sites designated by states within a day.

This week on Tuning into the C-Suite, listeners are tuning into the next feature of the Meet the Board Series where Managed Healthcare Executive Senior Editor Peter Wehrwein and Associate Editor Briana Contreras speak with MHE’s Board Member Kevin Ronneberg, M.D. Kevin is vice president and associate medical director for health initiatives at HealthPartners, an integrated, nonprofit provider and health insurance company located in Bloomington, Minnesota. During the conversation we got to learn more about Kevin, personally, and how he and his family are doing during the pandemic and his thoughts of the current issues healthcare is facing today.

Two newly approved antibody-drug conjugates and changes in radiation therapy lead the way.

There is growing recognition among healthcare providers and payers that disease prevalence is inextricably tied to social and environmental factors that impact health. In fact, clinical care accounts for an estimated 20% of health outcomes, while 80% are the result of social determinants of health (SDOH).

The Trump administration’s push to get more Medicare Shared Savings Program (MSSP) ACOs to take on downside risk is having an effect, but there are still many nontakers.

The United States usually doesn’t fare very well in international health comparisons. The country’s healthcare ranks among, if not the, most expensive. The outcomes, as measured by metrics such as life expectancy at birth, are not top tier, especially when the U.S. is compared to well-off countries in Europe and Asia.

Entresto (sacubitril-valsartan) didn’t get a lot of love from payers after it was approved in 2015 because of its expense and the crowded armamentarium for heart failure. But Entresto has since made its way into guidelines for reduced ejection fraction heart failure, sometimes called systolic heart failure.

Dr. Anthony Fauci addresses the American Heart Association Scientific Sessions.

Merck earned a new indication for pembrolizumab (Keytruda), in combination with chemotherapy, to treat locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC).

Manufacturing issue creates setback for Alkermes on much-anticipated therapy that mitigates weight gain.

After an FDA denial and a lost sponsor, sotagliflozin shows it can cut cardiovascular events and possibly treat a form of heart failure that has no approved therapies.

Community-based organizations should position themselves as groups with a deep, working knowledge of an area's geography, communities and residents.

Some employers would benefit if their older employees go on Medicare, and people in their 60s would have some safety net if they can't find a job with benefits. Provider revenues might take a hit because of lower Medicare reimbursement.

A Cleveland Clinic scientist stopped short of saying doctors should take patients off Vascepa, but he said he has questions due to the lack of a "neutral comparator."

Researchers say their study is the first to look at race as a factor in how people with diabetic macular edema respond to treatment with Avastin.

Overall, the Polycap polypill (simvastatin, atenolol, hydrochlorothiazide, ramipril) falls well short of the high expectations for the polypill approach to cardiovascular disease risk reduction.

The findings are the first in a series of six studies involving a registry supported by drug makers in the diabetes, cardiovascular, and heart failure space.